Gentle walking after meals to stimulate motility
Globally, it is projected that over 191 million people will be affected by it by 2030, with around 56 million experiencing vision-threatening stages of the disease
Tirzepatide (Generic Mounjaro): A dual GLP-1 and GIP receptor agonist, FDA-approved for type 2 diabetes and used off-label for weight loss
"For people whose body does not adapt, they should definitely connect with their doctor and understand this better whether they should continue with it." Dr G Moinuddin, on the other hand, says, "With Tiraziptide, some cases of kidney injury have also been reported." As per the US FDA this is a possibility
Branco V, Godinho-Santos A, Gonalves J, Lu J, Holmgren A, Carvalho C (2014) Mitochondrial thioredoxin reductase inhibition, selenium status, and Nrf-2 activation are determinant factors modulating the toxicity of mercury compounds